TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $83 | -42.8% | 9,307 | -1.6% | 0.00% | -50.0% |
| Q2 2023 | $145 | -32.2% | 9,454 | -0.6% | 0.01% | -33.3% |
| Q1 2023 | $214 | +6.5% | 9,508 | -0.3% | 0.01% | 0.0% |
| Q4 2022 | $201 | -99.9% | 9,541 | -16.9% | 0.01% | -18.2% |
| Q3 2022 | $283,000 | -19.4% | 11,477 | -20.8% | 0.01% | +10.0% |
| Q2 2022 | $351,000 | -5.9% | 14,485 | +0.2% | 0.01% | +11.1% |
| Q1 2022 | $373,000 | -27.6% | 14,461 | -12.9% | 0.01% | -18.2% |
| Q4 2021 | $515,000 | +28.4% | 16,601 | +0.4% | 0.01% | +22.2% |
| Q3 2021 | $401,000 | +59.8% | 16,527 | -4.1% | 0.01% | +80.0% |
| Q2 2021 | $251,000 | -38.3% | 17,237 | +5.7% | 0.01% | -37.5% |
| Q1 2021 | $407,000 | +116.5% | 16,307 | +137.0% | 0.01% | +100.0% |
| Q4 2020 | $188,000 | – | 6,881 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |